Drug Profile

EDIT 103

Alternative Names: EDIT-103

Latest Information Update: 15 May 2024

Price :

$50 ^*

Note:

Adis is an information provider. We do not sell or distribute actual drugs.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

Originator Editas Medicine
Class Eye disorder therapies; Gene therapies
Mechanism of Action Gene modulators

Orphan Drug Status

Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

No
New Molecular Entity No
Available For Licensing Yes - Retinitis pigmentosa

Highest Development Phases

Preclinical Retinitis pigmentosa

Most Recent Events

08 May 2024 Editas Medicine initiates appeal of the Patent Trial and Appeal Board decision favouring Broad Institute for CRISPR patent interference in the USA
09 Jan 2023 EDIT 103 is available for licensing as of 09 Jan 2023. http://www.editasmedicine.com 9378305
13 Oct 2022 Pharmacodynamics data from a preclinical trial in retinitis pigmentosa released by Editas Medicine

You need to be a logged in or subscribed to view this content

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial (opens in a new window)

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com